Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03093909 · ClinicalTrials.gov registry record · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
A Phase 1 study of Malignant Neoplasms of Female Genital Organs and Malignant Neoplasms of Independent (Primary) Multiple Sites, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT03093909 is a Phase 1 study of Malignant Neoplasms of Female Genital Organs and Malignant Neoplasms of Independent (Primary) Multiple Sites that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 44 participants, above the 35-participant average among 5 other Malignant Neoplasms of Female Genital Organs trials with a reported enrollment target (26% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03093909, a Phase 1 study of Malignant Neoplasms of Female Genital Organs and Malignant Neoplasms of Independent (Primary) Multiple Sites, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by inhalation (breathing it as a mist) to patients with solid tumors that have spread to the lungs from other parts of the body. The safety and side effects of this drug will also be studied. This is an investigational study. Gemcitabine is FDA approved and commercially available for the treatment of pancreatic and lung cancer, and other solid tumors. Its administration by inhalation is investigational. The study doctor can explain how the study drug is designed to work. Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.
Conditions Studied
Interventions
- DRUG Gemcitabine
Study Locations (1)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2017-11-22 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03093909
The ClinicalTrials.gov registry entry for NCT03093909 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 35-participant average among 5 other Malignant Neoplasms of Female Genital Organs trials with a reported enrollment target (26% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Malignant Neoplasms of Female Genital Organs appearing as the primary indexed condition, and to 1 intervention - of which Gemcitabine is the first listed.
NCT03093909 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03093909 about?
NCT03093909 is a clinical study titled "Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases". Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by inhalation (breathing it as a mist) to patients with solid tumors that have sp...
What is the current status of trial NCT03093909?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2017-11-22. Estimated completion is 2027-11-30.
What conditions does trial NCT03093909 study?
This clinical trial studies the following conditions: Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Melanoma and Other Malignant Neoplasms of Skin, Malignant Neoplasms of Mesothelial and Soft Tissue.
What interventions are being tested in trial NCT03093909?
The interventions under investigation include: Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT03093909?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03093909 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasms of Female Genital Organs
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Selumetinib and Olaparib in Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
ACTIVE NOT RECRUITING · Phase 1
-
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Malignant Neoplasms of Female Genital Organs
All registered trials for this condition
Malignant Neoplasms of Independent (Primary) Multiple Sites
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.